PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy
HONG KONG , Aug. 11, 2025 /PRNewswire/ --  Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind ...
2025-08-11T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Philippines' AC Health partners with Singapore's ABC Impact in vision to transform health for every Filipino
MANILA, Philippines , Aug. 11, 2025 /PRNewswire/ -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the Singapore -based impact investor dedicated ...
2025-08-11T    Health Care/Hospital   Medical/Pharmaceuticals 
HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment
SINGAPORE , Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus , its second Laboratory ...
2025-08-11T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical Equipment 
Brain Navi Biotechnology's NaoTrac performs first surgeries in Spain
Brain Navi has officially landed in Spain ! ...
2025-08-11T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Hugel launches botulinum toxin Letybo in Malaysia
- The company strengthens brand experience for local medical professionals through academic events and hands-on workshops ...
2025-08-11T    Health Care/Hospital   Medical/Pharmaceuticals 
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. ...
2025-08-09T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical Equipment 
GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology
PISCATAWAY, N.J. , Aug. 8, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, today unveiled its new global brand platform: Scripting Possibilities—a ...
2025-08-08T    Biotechnology   Health Care/Hospital 
Career-switching professionals, twins and trailblazers: Duke-NUS' Class of 2029 redefines path to medicine
78 students embark on their journey to become doctors at Duke-NUS Medical School's 19th White Coat Ceremony 46 individuals have made the shift from other careers into medicine , including a lawyer ...
2025-08-08T    Education   Health Care/Hospital   Higher Education   Medical/Pharmaceuticals 
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
YANTAI, China , Aug. 8, 2025 /PRNewswire/ -- On August 8 th , RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical ...
2025-08-08T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
AXA Signs Cooperation Agreement with Hainan Boao Lecheng Administration
Jointly explore innovative medical insurance services to provide customers with diverse and high-quality healthcare options ...
2025-08-08T    Health Care/Hospital   Insurance 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.